Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
WITH one day to go before it trades on the Catalist, late-stage specialty pharmaceutical firm iX Biopharma has already caught the eyes of interested parties.
This might have something to do with the firm's niche, which lies in the development and commercialisation of...